HR Execs on the Move

BioServe

www.bioserve.com

 
BioServe is a Beltsville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Sree Panuganti
Chief Scientits R&D Profile

Similar Companies

Champignon Brands

Champignon Brands is intent on being a global, vertically integrated producer of artisanal medicinal mushrooms and associated products. The Champignon team is focused on enhancing the health and wellness of millions of consumers who can benefit from its premium suite of organic, sustainable and non-GMO mushroom formulations. Champignon`s mushroom-derived CPG portfolio includes our flagship brand, Vitality Superteas. Our Vitality Superteas` SKUs are formulated with with the goal of revolutionizing conventional organic tea through the infusion of a proprietary blend of artisanal mushrooms with medicinal properties.

Seed IP

Seed IP is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southwest FLA Regional Imaging

Southwest FLA Regional Imaging is a Punta Gorda, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sigma-Tau Pharmaceuticals

Sigma-Tau Pharmaceuticals is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kiadis

Kiadis Pharma is a clinical stage biopharmaceutical company focused on developing innovative and potentially life-saving therapies for blood cancer patients where pharmacological standard of care is no longer an alternative. The Company`s main focus is on the development of a cellular therapeutic that will enable partially mismatched donor stem cell transplants from family members in blood cancer patients, thus making them safe and available as the last potentially life saving option. Stem cell transplantation is currently the only potentially curative treatment available for late stage blood cancer patients; however, a standard of care matching donor is only available for half of patients who are progressing with radiation therapy and chemotherapy.